Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date
Public ClinicalTrials.gov record NCT00691483. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.
Study identification
- NCT ID
- NCT00691483
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 659 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2008 (Type not available)
- Primary completion
- Sep 2009 (Actual)
- Completion
- Dec 2009 (Actual)
- Last update posted
- Nov 20, 2015
2008 – 2009
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Litchfield Park | Arizona | 85340 | — |
| Pfizer Investigational Site | Los Angeles | California | 90095 | — |
| Pfizer Investigational Site | Santa Ana | California | 92705 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66212 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40509 | — |
| Pfizer Investigational Site | Milford | Massachusetts | 01757 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68116-2004 | — |
| Pfizer Investigational Site | Endwell | New York | 13760 | — |
| Pfizer Investigational Site | Bridgeville | Pennsylvania | 15017 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19146 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00691483, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2015 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00691483 live on ClinicalTrials.gov.